<DOC>
	<DOCNO>NCT00991133</DOCNO>
	<brief_summary>This open-label study Clofarabine , Etoposide , Cyclophosphamide , PEG-asparaginase , Vincristine ass 5-drug treatment 's safety tolerability pediatric patient first relapse Acute Lymphoblastic Leukemia ( ALL ) .</brief_summary>
	<brief_title>A Safety Tolerability Study Clofarabine , Etoposide , Cyclophosphamide , PEG-asparaginase , Vincristine Pediatric Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>The trial Phase 1 , open-label study ass safety tolerability incorporate clofarabine intensive chemotherapy regimen etoposide , cyclophosphamide , PEG-asparaginase , vincristine . Patients enrol study receive maximum 2 cycle 5-drug regimen , treat accord investigator discretion . After study treatment period , patient follow minimum 4 month beyond final study visit . This study include maximum 12 evaluable patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Be first relapse &gt; 25 % blast bone marrow duration first remission ≥6 month longer intensive phase ( ) initial ALL therapy ( e.g. , patient maintenance continuation phase therapy [ beyond ] complete induction intensification phase ) . Have receive 2 prior induction regimens prior date first relapse . Patients first relapse fail reinduction attempt ( i.e. , 1 cycle reinduction therapy ) eligible inclusion study . Be ≥1 ≤30 year old body weight &gt; 10 kg study entry . ( Note : 3 patient age &gt; 21 ≤30 enrol . ) Be able receive study drug know contraindication . Be able provide adequate venous access . Have Karnofsky Performance Status ( KPS ) ≥50 patient &gt; 10 year age Lansky Performance Status ( LPS ) ≥50 patient ≤10 year age . Patients ( ≥18 year age ) parent legal guardian ( ) ( patient &lt; 18 year age ) must provide sign , write informed consent accord local institutional review board ( IRB ) institutional requirement . For patient &lt; 18 year age , sign assent obtain accord local IRB institutional requirement . Be able comply study procedure followup examination . Have adequate liver , renal , pancreatic , cardiac function consider acceptable laboratory value cardiac assessment Have active central nervous system ( CNS ) leukemia , evidence negative cytology lumbar puncture absence clinical central neurologic symptom . Diagnostic lumbar puncture perform eligibility assessment complete review , except bone marrow aspirate and/or biopsy . Patients CNS1 CNS2 leukemia may enrol study . Have recover baseline toxicity prior chemotherapy regimen prior enrollment study . Have receive previous treatment clofarabine . Have history clinical allergy ( Grade 3 4 ) PEGasparaginase . Have history severe pancreatitis ( Grade 3 4 ) attribute asparaginase therapy . Have Burkitt 's leukemia . Have overt testicular relapse . Adequate time elapse since patient 's last therapy . Patients relapse receive standard ALL maintenance chemotherapy require washout period entry onto study . Note patient may receive intrathecal ( IT ) araC , methotrexate , hydrocortisone immediately prior administration study drug . Patients may also receive hydroxyurea 24 hour prior start study therapy . Patients relapse receive standard ALL maintenance therapy must fully recover acute toxic effect prior therapy ( exclude hematologic toxicity ) , immunotherapy radiotherapy . Have uncontrolled systemic fungal , bacterial , viral , infection . For patient history fever within precede 3 day time enrollment , documentation negative blood culture least 48 hour require . Are pregnant lactate . Male female patient fertile must agree use effective mean birth control ( i.e. , latex condom , diaphragm , cervical cap , etc . ) study therapy , minimum 1 month follow final study visit . Have psychiatric disorder would interfere consent , study participation , followup . Have severe concurrent disease , history serious organ dysfunction disease involve heart , kidney , liver , pancreas . Have receive stem cell transplantation highdose chemotherapy stem cell rescue regimen . Have history cirrhosis know human immunodeficiency virus ( HIV ) /acquired immunodeficiency syndrome ( AIDS ) . Have history least 1 positive test hepatitis B hepatitis C infection . Have Down syndrome . Are currently participate another concurrent investigational treatment protocol .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>